Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
Graziela Zibetti Dal Molin, Kohei Omatsu, Anil K. Sood, et al.
Therapeutic Advances in Medical Oncology (2018) Vol. 10
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 158
PARP Inhibition in Cancer: An Update on Clinical Development
Esha Sachdev, Roya Tabatabai, Varun Yadav Roy, et al.
Targeted Oncology (2019) Vol. 14, Iss. 6, pp. 657-679
Closed Access | Times Cited: 155
Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis
Xiaoran Long, Keqi Song, Hao Hu, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 110
Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice
Hamad Ghaleb Dailah, Abdullah Abdu Hommdi, Mahdi Dafer Koriri, et al.
Heliyon (2024) Vol. 10, Iss. 2, pp. e24559-e24559
Open Access | Times Cited: 10
Current Ovarian Cancer Maintenance Strategies and Promising New Developments
Vinaya Gogineni, Susan Morand, Hannah Staats, et al.
Journal of Cancer (2020) Vol. 12, Iss. 1, pp. 38-53
Open Access | Times Cited: 61
The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction
Yue Zhao, Liu‐Xia Zhang, Ting Jiang, et al.
European Journal of Medicinal Chemistry (2020) Vol. 203, pp. 112570-112570
Closed Access | Times Cited: 60
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma
David M. O’Malley, Amit M. Oza, Domenica Lorusso, et al.
Gynecologic Oncology (2022) Vol. 167, Iss. 3, pp. 404-413
Open Access | Times Cited: 26
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions
Chunxue Zhang, Yaru Sheng, Xiao Sun, et al.
Cancer and Metastasis Reviews (2023) Vol. 42, Iss. 3, pp. 891-925
Open Access | Times Cited: 13
PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review
Sarah Cook, Anna V. Tinker
BioDrugs (2019) Vol. 33, Iss. 3, pp. 255-273
Closed Access | Times Cited: 42
Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes
Bruna Corradetti, Simone Pisano, R. Steven Conlan, et al.
Journal of Pharmacology and Experimental Therapeutics (2019) Vol. 370, Iss. 3, pp. 636-646
Open Access | Times Cited: 33
Translational Theragnosis of Ovarian Cancer: where do we stand?
Maria Grazia Perrone, Oreste Luisi, Anna Grassi, et al.
Current Medicinal Chemistry (2019) Vol. 27, Iss. 34, pp. 5675-5715
Closed Access | Times Cited: 33
Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis
Nicholas Adrianto, Ghea Mangkuliguna, Eunike Jennifer Tandiono, et al.
Taiwanese Journal of Obstetrics and Gynecology (2024) Vol. 63, Iss. 5, pp. 601-609
Open Access | Times Cited: 3
Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers
Jarosław Przybyciński, Magdalena Nalewajska, Małgorzata Marchelek‐Myśliwiec, et al.
Expert Opinion on Therapeutic Targets (2019) Vol. 23, Iss. 9, pp. 773-785
Closed Access | Times Cited: 24
DNA repair pathways in breast cancer: from mechanisms to clinical applications
Muhammad Tufail
Breast Cancer Research and Treatment (2023) Vol. 200, Iss. 3, pp. 305-321
Closed Access | Times Cited: 7
PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
Michelle D.S. Lightfoot, Lauren Montemorano, Kristin Bixel
Current Oncology Reports (2020) Vol. 22, Iss. 3
Closed Access | Times Cited: 20
A Comprehensive Review on PARP Inhibitors in Targeted Therapy for Cancers
Mounika Guduri, Samyuktha Kolluru, Haritha Pasupulati, et al.
Deleted Journal (2024) Vol. 19, Iss. 2, pp. 44-59
Open Access | Times Cited: 2
Targeting Replication Stress Response Pathways to Enhance Genotoxic Chemo- and Radiotherapy
Jac A. Nickoloff
Molecules (2022) Vol. 27, Iss. 15, pp. 4736-4736
Open Access | Times Cited: 11
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Isaac Yi Kim, Sinae Kim, Arnav Srivastava, et al.
BMC Urology (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 11
NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors
Takahito Miyake, Sunila Pradeep, Emine Bayraktar, et al.
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 8, pp. 1727-1735
Open Access | Times Cited: 10
RAD50 Deficient in a Breast Cancer Model Predicts Sensitivity to PARP Inhibitors
Cíntia Regina Niederauer Ramos, Renato José da Silva Oliveira, Marcela N. Rosa, et al.
Current Cancer Drug Targets (2023) Vol. 23, Iss. 11, pp. 900-909
Closed Access | Times Cited: 3
Templated Insertions Are Associated Specifically with BRCA2 Deficiency and Overall Survival in Advanced Ovarian Cancer
Grace Moore, Rahul Majumdar, Simon N. Powell, et al.
Molecular Cancer Research (2022) Vol. 20, Iss. 7, pp. 1061-1070
Open Access | Times Cited: 4
Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches
Giulia Marvaso, Giulia Corrao, Mattia Zaffaroni, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 4
Role of Clinical Pharmacodynamics Studies in the Era of Precision Medicines Against Cancer
Fatih M. Uckun, Sanjive Qazi
Springer eBooks (2018), pp. 1-18
Closed Access | Times Cited: 2
The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer
Ciyu Yang, Angela G. Arnold, Amanda Catchings, et al.
Breast Cancer Research and Treatment (2021) Vol. 185, Iss. 3, pp. 869-877
Open Access | Times Cited: 2
Research progress in the treatment of partial platinum-sensitive recurrent ovarian cancer.
Miaochen Zhu, Jing Wang, Yiyuan Wuna, et al.
Zhongnan Daxue xuebao. Yixue ban (2021) Vol. 46, Iss. 6, pp. 644-652
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top